Oncolytic virus bispecific gene delivery for high grade gliomas

用于高级别神经胶质瘤的溶瘤病毒双特异性基因递送

基本信息

项目摘要

Overall Center Abstract This application describes the Pediatric Ohio-New York Cancer (Peds-ONC) Immunotherapy Center, created in response to the RFA as a second nidus for the Pediatric Immunotherapy Discovery and Development Consortium (PI-DDN). To complement the funded U54 (Maris and Mackall, MPI) of the PI-DDN that largely seeks to harness adaptive immunity to further develop CAR-T cells against newly identified antigens, we propose to harness innate immunity to target pediatric cancers, to circumvent resistance to conventional therapy, and to further enable adaptive/hybrid immune approaches. Our aims are to (1) Identify and overcome barriers to utilizing NK and CAR-NK cells as cancer therapeutics, (2) break tolerance to “self” cancer-associated proteins and (3) enhance immunotherapies by targeting suppressive myeloid cells. We will accomplish our aims through four projects, based at two major sites based in Ohio (Nationwide Children’s Hospital) and New York (New York Medical College) with subsites in Columbus (The Ohio State University) and Minneapolis (Univeristy of Minnesota). In addition to an Administrative Shared Resource (Core A, directed by Dr. Timothy Cripe and Associate Director Dr. Mitchell Cairo), the projects are scientifically supported by a comprehensive Genomics & Immune Monitoring Shared Resource (Core B, directed by Dr. Elaine Mardis with several subspecialy assistant directors). Core B provides integrated datasets via state- of-the-art technologies including mass cytometry, single cell transcriptomics, and an array of other genomics approaches that enable detailed characterizations and tracking of cancer cell immunogenicity, the tumor immune microenvironment, and immunologic responses. We have also assembled strong external and internal scientific advisory boards of renowned leaders whose expertise spans the projects and shared resources. The projects are highly integrated and cross-informative. We propose that therapeutic regimens that combine modalities will produce synergy that drives anti-tumor immune responses in preclinical pediatric cancer models, overcoming the limitations of low mutational burdens. Our goal is to generate a sufficient body of knowledge with compelling data to inform the rational design of future clinical trials and thereby improve the lives of children with cancer. 1
总体中心摘要 此应用程序描述了儿科俄亥俄-纽约癌症 (Peds-ONC) 免疫治疗中心,该中心创建于 对 RFA 的响应是儿科免疫疗法发现和开发的第二个巢穴 联盟(PI-DDN)。为了补充 PI-DDN 资助的 U54(Maris 和 Mackall,MPI), 我们建议,寻求利用适应性免疫进一步开发针对新发现抗原的 CAR-T 细胞 利用先天免疫来针对儿科癌症,规避对传统疗法的耐药性,并 进一步实现适应性/混合免疫方法。 我们的目标是 (1) 识别并克服利用 NK 和 CAR-NK 细胞作为癌症疗法的障碍,(2) 打破对“自身”癌症相关蛋白的耐受性,以及(3)通过靶向抑制来增强免疫治疗 骨髓细胞。我们将通过位于俄亥俄州两个主要基地的四个项目来实现我们的目标 (全国儿童医院)和纽约(纽约医学院)在哥伦布(The 俄亥俄州立大学)和明尼阿波利斯大学(明尼苏达大学)。除了管理共享之外 资源(核心 A,由 Timothy Cripe 博士和副主任 Mitchell Cairo 博士指导),项目是 由综合基因组学和免疫监测共享资源(核心 B,指导)提供科学支持 由 Elaine Mardis 博士和几位专科助理主任负责)。核心 B 通过状态提供集成数据集 最先进的技术,包括质谱流式分析、单细胞转录组学和一系列其他基因组学 能够详细表征和跟踪癌细胞免疫原性、肿瘤免疫的方法 微环境和免疫反应。我们还聚集了强大的外部和内部科学 由知名领导者组成的顾问委员会,其专业知识涵盖项目和共享资源。项目 高度集成和交叉信息。我们建议结合各种方式的治疗方案将 产生协同作用,在临床前儿科癌症模型中驱动抗肿瘤免疫反应,克服 低突变负担的局限性。我们的目标是生成足够的、具有说服力的知识体系 数据为未来临床试验的合理设计提供信息,从而改善癌症儿童的生活。 1

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TIMOTHY P CRIPE其他文献

TIMOTHY P CRIPE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TIMOTHY P CRIPE', 18)}}的其他基金

Project 4:Targeting M2-like Macrophages and MDSC with Myelolytic-Virotherapy
项目 4:利用溶髓病毒疗法靶向 M2 样巨噬细胞和 MDSC
  • 批准号:
    10885260
  • 财政年份:
    2023
  • 资助金额:
    $ 36.69万
  • 项目类别:
Project 4:Targeting M2-like Macrophages and MDSC with Myelolytic-Virotherapy
项目 4:利用溶髓病毒疗法靶向 M2 样巨噬细胞和 MDSC
  • 批准号:
    10885263
  • 财政年份:
    2023
  • 资助金额:
    $ 36.69万
  • 项目类别:
Novel Immunomodulation and Facilitation of “Suppression Proof” CAR NK cell against Ewing sarcoma
新型免疫调节和促进“抑制证明”CAR NK 细胞对抗尤文肉瘤
  • 批准号:
    10834579
  • 财政年份:
    2023
  • 资助金额:
    $ 36.69万
  • 项目类别:
Training Program in Basic and Translational Pediatric Oncology Research
基础和转化儿科肿瘤学研究培训计划
  • 批准号:
    10408197
  • 财政年份:
    2022
  • 资助金额:
    $ 36.69万
  • 项目类别:
Admin-Core-001
管理核心-001
  • 批准号:
    10707766
  • 财政年份:
    2022
  • 资助金额:
    $ 36.69万
  • 项目类别:
Admin-Core-001
管理核心-001
  • 批准号:
    10707767
  • 财政年份:
    2022
  • 资助金额:
    $ 36.69万
  • 项目类别:
Overcoming Immunological Tumor Microenvironment Resistance in Ewing Sarcoma
克服尤文肉瘤的免疫肿瘤微环境耐药性
  • 批准号:
    10616121
  • 财政年份:
    2022
  • 资助金额:
    $ 36.69万
  • 项目类别:
Core A:Administrative Core
核心A:行政核心
  • 批准号:
    10680851
  • 财政年份:
    2022
  • 资助金额:
    $ 36.69万
  • 项目类别:
Training Program in Basic and Translational Pediatric Oncology Research
基础和转化儿科肿瘤学研究培训计划
  • 批准号:
    10590705
  • 财政年份:
    2022
  • 资助金额:
    $ 36.69万
  • 项目类别:
IL1RAP CAR NK cells enhance targeting of Ewing Sarcoma (ES) alone and with combinatorial targeted immunotherapy
IL1RAP CAR NK 细胞单独或联合靶向免疫疗法可增强对尤文肉瘤 (ES) 的靶向作用
  • 批准号:
    10401167
  • 财政年份:
    2021
  • 资助金额:
    $ 36.69万
  • 项目类别:

相似海外基金

Collaboration in Regulatory Systems Strengthening and Standardization Activities to Increase Global Access to Safe and Effective Biological Products.
加强监管系统和标准化活动方面的合作,以增加全球获得安全有效的生物产品的机会。
  • 批准号:
    10448926
  • 财政年份:
    2021
  • 资助金额:
    $ 36.69万
  • 项目类别:
Collaboration in Regulatory Systems Strengthening and Standardization Activities to Increase Global Access to Safe and Effective Biological Products.
加强监管系统和标准化活动方面的合作,以增加全球获得安全有效的生物产品的机会。
  • 批准号:
    10491861
  • 财政年份:
    2021
  • 资助金额:
    $ 36.69万
  • 项目类别:
Collaboration in Regulatory Systems Strengthening and Standardization Activities to Increase Global Access to Safe and Effective Biological Products.
加强监管系统和标准化活动方面的合作,以增加全球获得安全有效的生物产品的机会。
  • 批准号:
    10675535
  • 财政年份:
    2021
  • 资助金额:
    $ 36.69万
  • 项目类别:
EPSRC Centre for Doctoral Training in Bioprocess Engineering Leadership (Complex Biological Products Manufacture)
EPSRC 生物过程工程领导力博士培训中心(复杂生物制品制造)
  • 批准号:
    EP/S021868/1
  • 财政年份:
    2019
  • 资助金额:
    $ 36.69万
  • 项目类别:
    Training Grant
Exploring interactions and benefits of novel microbial biological products in blueberry propagation
探索新型微生物生物制品在蓝莓繁殖中的相互作用和益处
  • 批准号:
    529840-2018
  • 财政年份:
    2018
  • 资助金额:
    $ 36.69万
  • 项目类别:
    Applied Research and Development Grants - Level 1
GOALI: Collaborative Research: Industrial Implementation of Smart Biopolymers for Purification of Biological Products
目标:合作研究:用于生物制品纯化的智能生物聚合物的工业实施
  • 批准号:
    1403724
  • 财政年份:
    2014
  • 资助金额:
    $ 36.69万
  • 项目类别:
    Standard Grant
GOALI: Collaborative Research: Industrial Implementation of Smart Biopolymers for Purification of Biological Products
目标:合作研究:用于生物制品纯化的智能生物聚合物的工业实施
  • 批准号:
    1403697
  • 财政年份:
    2014
  • 资助金额:
    $ 36.69万
  • 项目类别:
    Standard Grant
Formulation and delivery approaches for water soluble biological products delivered through the skin focussing on L-Ascorbic Acid.
通过皮肤输送的水溶性生物产品的配方和输送方法,重点是 L-抗坏血酸。
  • 批准号:
    131690
  • 财政年份:
    2014
  • 资助金额:
    $ 36.69万
  • 项目类别:
    Feasibility Studies
Formulation and stability of biological products for skin delivery focussing on Retinol.
以视黄醇为重点的皮肤输送生物制品的配方和稳定性。
  • 批准号:
    131338
  • 财政年份:
    2013
  • 资助金额:
    $ 36.69万
  • 项目类别:
    Feasibility Studies
Demonstrate the effectiveness of antimicrobial protection of new types of Biological Products
展示新型生物制品抗菌保护的有效性
  • 批准号:
    429734-2011
  • 财政年份:
    2012
  • 资助金额:
    $ 36.69万
  • 项目类别:
    Experience Awards (previously Industrial Undergraduate Student Research Awards)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了